Cargando…
Efficacy of intranasal LaAg vaccine against Leishmania amazonensis infection in partially resistant C57Bl/6 mice
BACKGROUND: We have previously demonstrated that intranasal vaccination of highly susceptible BALB/c mice with whole Leishmania amazonensis antigens (LaAg) leads to protection against murine cutaneous leishmaniasis. Here, we evaluate the response of partially resistant C57BL/6 mice to vaccination as...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5052793/ https://www.ncbi.nlm.nih.gov/pubmed/27716449 http://dx.doi.org/10.1186/s13071-016-1822-9 |
_version_ | 1782458288122626048 |
---|---|
author | Pratti, Juliana Elena Silveira Ramos, Tadeu Diniz Pereira, Joyce Carvalho da Fonseca-Martins, Alessandra Marcia Maciel-Oliveira, Diogo Oliveira-Silva, Gabriel de Mello, Mirian França Chaves, Suzana Passos Gomes, Daniel Claudio Oliveira Diaz, Bruno Lourenço Rossi-Bergmann, Bartira de Matos Guedes, Herbert Leonel |
author_facet | Pratti, Juliana Elena Silveira Ramos, Tadeu Diniz Pereira, Joyce Carvalho da Fonseca-Martins, Alessandra Marcia Maciel-Oliveira, Diogo Oliveira-Silva, Gabriel de Mello, Mirian França Chaves, Suzana Passos Gomes, Daniel Claudio Oliveira Diaz, Bruno Lourenço Rossi-Bergmann, Bartira de Matos Guedes, Herbert Leonel |
author_sort | Pratti, Juliana Elena Silveira |
collection | PubMed |
description | BACKGROUND: We have previously demonstrated that intranasal vaccination of highly susceptible BALB/c mice with whole Leishmania amazonensis antigens (LaAg) leads to protection against murine cutaneous leishmaniasis. Here, we evaluate the response of partially resistant C57BL/6 mice to vaccination as a more representative experimental model of human cutaneous leishmaniasis. METHODS: C57BL/6 mice from different animal facilities were infected with L. amazonensis (Josefa strain) to establish the profile of infection. Intranasal vaccination was performed before the infection challenge with two doses of 10 μg of LaAg alone or associated with the adjuvant ADDAVAX® by instillation in the nostrils. The lesion progression was measured with a dial caliper and the parasite load by limited dilution assay in the acute and chronic phases of infection. Cytokines were quantified by ELISA in the homogenates of infected footpads. RESULTS: C57BL/6 mice from different animal facilities presented the same L. amazonensis infection profile, displaying a progressive acute phase followed by a controlled chronic phase. Parasites cultured in M199 and Schneider’s media were equally infective. Intranasal vaccination with LaAg led to milder acute and chronic phases of the disease. The mechanism of protection was associated with increased production of IFN-gamma in the infected tissue as measured in the acute phase. Association with the ADDAVAX® adjuvant did not improve the efficacy of intranasal LaAg vaccination. Rather, ADDAVAX® reduced vaccination efficacy. CONCLUSION: This study demonstrates that the efficacy of adjuvant-free intranasal vaccination with LaAg is extendable to the more resistant C57Bl/6 mouse model of infection with L. amazonensis, and is thus not exclusive to the susceptible BALB/c model. These results imply that mucosal immunomodulation by LaAg leads to peripheral protection irrespective of the genetic background of the host. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13071-016-1822-9) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5052793 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-50527932016-10-06 Efficacy of intranasal LaAg vaccine against Leishmania amazonensis infection in partially resistant C57Bl/6 mice Pratti, Juliana Elena Silveira Ramos, Tadeu Diniz Pereira, Joyce Carvalho da Fonseca-Martins, Alessandra Marcia Maciel-Oliveira, Diogo Oliveira-Silva, Gabriel de Mello, Mirian França Chaves, Suzana Passos Gomes, Daniel Claudio Oliveira Diaz, Bruno Lourenço Rossi-Bergmann, Bartira de Matos Guedes, Herbert Leonel Parasit Vectors Research BACKGROUND: We have previously demonstrated that intranasal vaccination of highly susceptible BALB/c mice with whole Leishmania amazonensis antigens (LaAg) leads to protection against murine cutaneous leishmaniasis. Here, we evaluate the response of partially resistant C57BL/6 mice to vaccination as a more representative experimental model of human cutaneous leishmaniasis. METHODS: C57BL/6 mice from different animal facilities were infected with L. amazonensis (Josefa strain) to establish the profile of infection. Intranasal vaccination was performed before the infection challenge with two doses of 10 μg of LaAg alone or associated with the adjuvant ADDAVAX® by instillation in the nostrils. The lesion progression was measured with a dial caliper and the parasite load by limited dilution assay in the acute and chronic phases of infection. Cytokines were quantified by ELISA in the homogenates of infected footpads. RESULTS: C57BL/6 mice from different animal facilities presented the same L. amazonensis infection profile, displaying a progressive acute phase followed by a controlled chronic phase. Parasites cultured in M199 and Schneider’s media were equally infective. Intranasal vaccination with LaAg led to milder acute and chronic phases of the disease. The mechanism of protection was associated with increased production of IFN-gamma in the infected tissue as measured in the acute phase. Association with the ADDAVAX® adjuvant did not improve the efficacy of intranasal LaAg vaccination. Rather, ADDAVAX® reduced vaccination efficacy. CONCLUSION: This study demonstrates that the efficacy of adjuvant-free intranasal vaccination with LaAg is extendable to the more resistant C57Bl/6 mouse model of infection with L. amazonensis, and is thus not exclusive to the susceptible BALB/c model. These results imply that mucosal immunomodulation by LaAg leads to peripheral protection irrespective of the genetic background of the host. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13071-016-1822-9) contains supplementary material, which is available to authorized users. BioMed Central 2016-10-06 /pmc/articles/PMC5052793/ /pubmed/27716449 http://dx.doi.org/10.1186/s13071-016-1822-9 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Pratti, Juliana Elena Silveira Ramos, Tadeu Diniz Pereira, Joyce Carvalho da Fonseca-Martins, Alessandra Marcia Maciel-Oliveira, Diogo Oliveira-Silva, Gabriel de Mello, Mirian França Chaves, Suzana Passos Gomes, Daniel Claudio Oliveira Diaz, Bruno Lourenço Rossi-Bergmann, Bartira de Matos Guedes, Herbert Leonel Efficacy of intranasal LaAg vaccine against Leishmania amazonensis infection in partially resistant C57Bl/6 mice |
title | Efficacy of intranasal LaAg vaccine against Leishmania amazonensis infection in partially resistant C57Bl/6 mice |
title_full | Efficacy of intranasal LaAg vaccine against Leishmania amazonensis infection in partially resistant C57Bl/6 mice |
title_fullStr | Efficacy of intranasal LaAg vaccine against Leishmania amazonensis infection in partially resistant C57Bl/6 mice |
title_full_unstemmed | Efficacy of intranasal LaAg vaccine against Leishmania amazonensis infection in partially resistant C57Bl/6 mice |
title_short | Efficacy of intranasal LaAg vaccine against Leishmania amazonensis infection in partially resistant C57Bl/6 mice |
title_sort | efficacy of intranasal laag vaccine against leishmania amazonensis infection in partially resistant c57bl/6 mice |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5052793/ https://www.ncbi.nlm.nih.gov/pubmed/27716449 http://dx.doi.org/10.1186/s13071-016-1822-9 |
work_keys_str_mv | AT prattijulianaelenasilveira efficacyofintranasallaagvaccineagainstleishmaniaamazonensisinfectioninpartiallyresistantc57bl6mice AT ramostadeudiniz efficacyofintranasallaagvaccineagainstleishmaniaamazonensisinfectioninpartiallyresistantc57bl6mice AT pereirajoycecarvalho efficacyofintranasallaagvaccineagainstleishmaniaamazonensisinfectioninpartiallyresistantc57bl6mice AT dafonsecamartinsalessandramarcia efficacyofintranasallaagvaccineagainstleishmaniaamazonensisinfectioninpartiallyresistantc57bl6mice AT macieloliveiradiogo efficacyofintranasallaagvaccineagainstleishmaniaamazonensisinfectioninpartiallyresistantc57bl6mice AT oliveirasilvagabriel efficacyofintranasallaagvaccineagainstleishmaniaamazonensisinfectioninpartiallyresistantc57bl6mice AT demellomirianfranca efficacyofintranasallaagvaccineagainstleishmaniaamazonensisinfectioninpartiallyresistantc57bl6mice AT chavessuzanapassos efficacyofintranasallaagvaccineagainstleishmaniaamazonensisinfectioninpartiallyresistantc57bl6mice AT gomesdanielclaudiooliveira efficacyofintranasallaagvaccineagainstleishmaniaamazonensisinfectioninpartiallyresistantc57bl6mice AT diazbrunolourenco efficacyofintranasallaagvaccineagainstleishmaniaamazonensisinfectioninpartiallyresistantc57bl6mice AT rossibergmannbartira efficacyofintranasallaagvaccineagainstleishmaniaamazonensisinfectioninpartiallyresistantc57bl6mice AT dematosguedesherbertleonel efficacyofintranasallaagvaccineagainstleishmaniaamazonensisinfectioninpartiallyresistantc57bl6mice |